WASHINGTON, Feb. 26 (TNSres) -- The American Academy of Allergy Asthma and Immunology issued the following news release on Feb. 25, 2024: * * * Study highlights a valuable option for safe and effective food allergy treatment. * * * Sixteen weeks of omalizumab results in a higher tolerated threshold for multiple food allergies according to new research presented today at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and published in the New England Journal o  more

WASHINGTON, Feb. 26 (TNSres) -- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases issued the following news release: * * * Drug Can Help Protect Kids With Multiple Food Allergies During Accidental Exposure * * * A 16-week course of a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could consume without an allergic reaction in a late-stage   more

WASHINGTON, Feb. 22 -- The Federal Communications Commission's Wireline Competition Bureau issued the following public notice (WC Docket No. 23-284): * * * Re: Copper Retirement Network Change Certification Received Verizon New England Inc. (Verizon), an incumbent local exchange carrier (LEC), has filed certification that public notice of network change(s) involving the retirement of copper has been provided through its publicly accessible Internet site, as required by section 51.329(a)(2) of  more

WASHINGTON, Feb. 25 -- The Federal Communications Commission's Wireline Competition Bureau issued the following public notice (WC Docket No. 24-56) on Feb. 23, 2024: * * * Re: Short Term Network Change Certification Received Verizon New England Inc. (Verizon), an incumbent local exchange carrier (LEC), has filed certification that short term public notice of network change(s) has been provided through its publicly accessible Internet site, as required by section 51.329(a)(2) of the rules of t  more

BALTIMORE, Maryland, Feb. 26 (TNSres) -- Johns Hopkins Medicine issued the following news release: * * * Results suggest omalizumab has the potential to be a 'life-changing' medication for patients with food allergy, including those with multiple food allergies * * * A study led by Johns Hopkins Children's Center shows omalizumab -- an injectable, Food and Drug Administration (FDA)-approved medication for treating asthma and other allergic conditions -- substantially reduced potentially life  more

CHAPEL HILL, North Carolina, Feb. 26 (TNSres) -- The University of North Carolina School of Medicine issued the following news release: * * * Published in the New England Journal of Medicine, Seth A. Berkowitz, MD, MPH, associate professor of medicine at the UNC School of Medicine, wrote perspective piece on how medically tailored meals address health consequences of food insecurity. * * * Eating a diet rich in a variety of healthy foods packed with antioxidants and nutrients is the gateway   more

CHAPEL HILL, North Carolina, Feb. 26 (TNSres) -- The University of North Carolina School of Medicine issued the following news release: * * * Stage one results from the OUtMATCH clinical trial, published in the New England Journal of Medicine, show that a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as age one could consume without an allergic reaction. Edwin Kim, MD, Corinne Keet, MD, PhD, and Mike K  more